Amedisys, Inc. (NASDAQ:AMED) Expected to Post Earnings of $1.11 Per Share

Wall Street brokerages expect Amedisys, Inc. (NASDAQ:AMEDGet Rating) to announce $1.11 earnings per share (EPS) for the current quarter, according to Zacks. Seven analysts have made estimates for Amedisys’ earnings, with estimates ranging from $1.06 to $1.16. Amedisys posted earnings per share of $1.54 during the same quarter last year, which indicates a negative year-over-year growth rate of 27.9%. The company is expected to report its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Amedisys will report full year earnings of $5.31 per share for the current financial year, with EPS estimates ranging from $5.23 to $5.41. For the next financial year, analysts expect that the business will report earnings of $6.45 per share, with EPS estimates ranging from $6.14 to $7.26. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Amedisys.

Amedisys (NASDAQ:AMEDGet Rating) last announced its earnings results on Wednesday, February 23rd. The health services provider reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.01. Amedisys had a return on equity of 21.84% and a net margin of 9.44%. The firm had revenue of $559.32 million during the quarter, compared to analyst estimates of $555.18 million. During the same period last year, the firm posted $1.49 EPS. The business’s revenue was up 1.6% compared to the same quarter last year.

Several equities research analysts have recently issued reports on AMED shares. Benchmark decreased their target price on Amedisys from $200.00 to $175.00 and set a “buy” rating for the company in a research report on Thursday, February 24th. BMO Capital Markets raised Amedisys from a “market perform” rating to an “outperform” rating and decreased their target price for the company from $210.00 to $190.00 in a research report on Friday, February 25th. Royal Bank of Canada decreased their price objective on Amedisys from $221.00 to $199.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Truist Financial decreased their price objective on Amedisys from $210.00 to $200.00 and set a “buy” rating for the company in a report on Friday, February 25th. Finally, StockNews.com began coverage on Amedisys in a report on Thursday, March 31st. They issued a “hold” rating for the company. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Amedisys currently has a consensus rating of “Buy” and a consensus target price of $193.56.

Shares of Amedisys stock opened at $135.85 on Friday. Amedisys has a 1 year low of $122.12 and a 1 year high of $292.97. The firm has a market cap of $4.42 billion, a PE ratio of 21.43, a P/E/G ratio of 2.63 and a beta of 0.72. The stock has a fifty day moving average price of $157.38 and a 200-day moving average price of $154.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.95 and a quick ratio of 0.95.

In other news, insider David L. Kemmerly sold 2,500 shares of Amedisys stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the completion of the sale, the insider now owns 16,336 shares in the company, valued at approximately $2,896,536.16. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Riverbridge Partners LLC lifted its position in Amedisys by 6.6% in the 1st quarter. Riverbridge Partners LLC now owns 1,693,656 shares of the health services provider’s stock worth $291,800,000 after buying an additional 104,906 shares during the last quarter. State Street Corp lifted its position in Amedisys by 0.5% in the 4th quarter. State Street Corp now owns 830,860 shares of the health services provider’s stock worth $134,500,000 after buying an additional 3,769 shares during the last quarter. William Blair Investment Management LLC lifted its position in Amedisys by 4.0% in the 3rd quarter. William Blair Investment Management LLC now owns 763,648 shares of the health services provider’s stock worth $113,860,000 after buying an additional 29,075 shares during the last quarter. Mackenzie Financial Corp lifted its position in Amedisys by 39,235.8% in the 4th quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock worth $92,331,000 after buying an additional 568,919 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in Amedisys in the 4th quarter worth approximately $85,286,000. Institutional investors own 92.18% of the company’s stock.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.